Stock Information
symbol line chart

CERSCerus Corp.

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

William M. Greenman

Location

California, USA

Exchange

Nasdaq

Website

https://cerus.com

Summary

Cerus Corporation focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.

Company Info

CEO

William M. Greenman

Location

California, USA

Exchange

Nasdaq

Website

https://cerus.com

Summary

Cerus Corporation focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.

AI Insights for CERS
2 min read

Quick Summary

Cerus Corporation is a medical technology company focused on blood safety and transfusion medicine. Its core business is the development and commercialization of the INTERCEPT Blood System, which is designed to reduce the risk of transfusion-transmitted infections by inactivating pathogens and certain white blood cells in blood components. The company sells systems, disposable kits, and related products for platelets, plasma, cryoprecipitate-derived products, and future red blood cell applications. Its main customers include blood centers, hospitals, transfusion services, government health systems, and distributors that support blood collection and processing. Cerus operates in the United States, Europe, the Middle East, Latin America, and other international markets, with commercial use reported across nearly 40 countries.

The Bull Case

  • Cerus has a strong niche position in pathogen-reduction technology for transfusion medicine, which is a specialized market with meaningful regulatory and clinical barriers.
  • Its INTERCEPT platelet franchise has a significant U.S.
  • position, with management estimating a mid-60% market share and potential room to exceed 70%.
  • The company has a recurring revenue model tied to disposable kits and blood component processing, which can create repeat demand once blood centers adopt the system.
  • Cerus also has international diversification, with commercial operations across nearly 40 countries and notable growth opportunities in EMEA, Germany, and the Middle East.

The Bear Case

  • Cerus remains unprofitable on a GAAP basis, and the provided fundamentals show negative net income and negative EPS.
  • Its valuation metrics are difficult to interpret because PriceToEarnings is not meaningful and EV/EBITDA appears very high, which can make the stock sensitive to changes in growth expectations.
  • The company is concentrated around the INTERCEPT platform, so product, regulatory, reimbursement, or adoption setbacks could have an outsized effect.
  • Cerus is relatively small, with about 290 employees and a market capitalization near $508 million, which can limit resources compared with larger healthcare competitors.
  • The stock also has elevated volatility, reflected in a beta of 1.77 and a trading range from $1.15 to $3.47 over the provided 52-week period.

Key Risks

  • Cerus faces regulatory risk because future growth depends in part on approvals, submissions, and study results for products such as INT200 and the red blood cell program.
  • Clinical trial risk is also meaningful, especially with U.S.
  • phase 3 red blood cell results expected later in 2026 and potential European regulatory decisions thereafter.
  • Commercial risk remains present because blood centers operate under budget constraints and may adopt new systems more slowly than management expects.

What to Watch

UpcomingDuring the recent update cycle, Cerus reported record 2025 revenue of $233.8 million, representing 16% growth, while product revenue exceeded prior guidance.
UpcomingThe company narrowed its GAAP net loss to $15.6 million and reported positive adjusted EBITDA for a seventh consecutive quarter, reaching $9.5 million for the year.
UpcomingINTERCEPT treated about 3 million blood components in 2025 for roughly 600,000 patients across nearly 40 countries, reinforcing the scale of the installed commercial base.
ExpectedIn the next quarter, investors are likely to focus on whether Cerus continues to track toward its reaffirmed 2026 product revenue guidance of $224 million to $228 million.

Price Drivers

  • Cerus’ stock price is likely driven by revenue growth, profitability progress, cash flow trends, regulatory milestones, and adoption of the INTERCEPT Blood System.
  • The company remains unprofitable on a GAAP basis in the provided fundamentals, with BasicEPS and DilutedEPS at -0.01 and net income negative, so investors may react strongly to evidence that losses are narrowing.
  • Recent news that 2025 revenue reached a record $233.8 million, adjusted EBITDA remained positive, and 2026 product revenue guidance was reaffirmed can support investor confidence.
  • The stock may also move on updates related to the INT200 U.S.

Recent News

  • Recent news highlighted that Cerus reported record 2025 revenue of $233.8 million, up 16%, with product revenue exceeding guidance.
  • The company reaffirmed 2026 product revenue guidance of $224 million to $228 million and reported positive adjusted EBITDA for a seventh straight quarter.
  • Cerus announced that its INT200 illuminator received CE mark approval and launched in Europe, with a U.S.
  • PMA submission planned around mid-2026.

Market Trends

  • The blood safety market is shaped by ongoing demand for safer transfusions, pathogen reduction, infection control, and standardized blood processing.
  • Hospitals and blood centers are increasingly focused on reducing transfusion-related risks while also managing inventory, wastage, labor, and cost pressures.
  • Regulatory and reimbursement frameworks can strongly influence adoption, especially in international markets such as Germany and in emerging opportunities across the Middle East and Asia.
  • Small-cap healthcare and medical equipment stocks are also affected by macro trends, including interest rates, investor risk appetite, access to capital, and broader market sentiment.

AI-generated summary. Not investment advice. DYOR.

Community Research

Research from investors like you

Be the first to share your analysis on CERS

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show